The Coalition Against Patent Abuse (CAPA) aims to stop Big Pharma from gaming the system to extend their monopolies at consumers’ expense. At CAPA we come together with the collective acknowledgment that America’s drug spending problem cannot be addressed without examining government-granted monopolies that prevent drug price competition for decades, but which do not represent either innovation or the best interests of public health. Essentially, patent abuse and extension of regulatory monopolies not only keep drug prices high, they also slow innovation and prevent timely access to better, affordable medicines to save and enhance patients’ lives.
Humira was approved in 2002, and it now makes more money annually than all of the NFL teams, combined.
Strengthen the policing power of the PTO, the patent system, and the courts to ensure that only true innovation is rewarded by patents and their government-granted monopolies.
Oppose efforts by Big Pharma and its allies to roll back IPR and U.S. Supreme Court rulings that make it easier to eliminate invalid, non-innovative patents.
Reduce and eliminate the legal and regulatory gamesmanship and chronic, late-stage patenting that stops generic and biosimilar competition in its tracks.
We are building a new coalition of healthcare providers and payers, consumer groups, patient advocacy organizations, employers, and other stakeholders to fight abuses of the patent system that can extend government-granted monopolies illegitimately for years, even decades.